Diagnostic deals surge as developers target more new drugs

Over the past three years the number of partnerships being inked between drug developers and diagnostics companies has soared, according to PricewaterhouseCoopers. And that's just the latest sign that diagnostic tests are playing an ever-increasing role in identifying patients most likely to benefit from a new treatment--which is especially true for expensive cancer drugs. Chalk it all up to the personalized medicine trend in biopharma, reports the Financial Times, as payers and regulators look for more drugs that have a higher chance of success. Article

 

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.